Business
Publication of Interim Results Delayed
Publication of Interim Results Delayed.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n \n (\"Allergy Therapeutics\", \"ATL\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n \n \n Publication of Interim Results Delayed\n \n \n \n \n \n \n \n 29 March 2023\n \n Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it will not publish its interim results for the six-month period to 31 December 2022 by 31 March 2023.\n \n \n \n \n \n On 29 December 2022, the Company announced a delay in the publication of its annual report and accounts for the year to 31 June 2022 due to delays in completing the audit. Consequently, the Company's shares were suspended from trading on 3 January 2023 and remain suspended.\n \n \n \n \n \n The Company is actively working to finalise the audit and publication of its 2022 annual report and accounts and its interim results.\n Allergy Therapeutics remains in active discussions regarding its funding situation and will update the market in due course.\n \n \n \n \n \n For further information on the Company\n , please visit the website\n :\n \n \n \n www.allergytherapeutics.com\n \n \n .\n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.\n \n \n \n \n \n \n \n \n \n - ENDS -\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n Allergy Therapeutics\n \n \n \n +44 (0) 1903 845 820\n \n \n Manuel Llobet, Chief Executive Officer\n \n \n Martin Hopcroft, Interim Chief Financial Officer\n \n \n \n \n \n \n Panmure Gordon (Nominated Adviser and Broker)\n \n \n \n +44 (0) 20 7886 2500\n \n \n Freddy Crossley, Emma Earl, Corporate Finance\n \n \n Rupert Dearden, Corporate Broking\n \n \n \n \n \n \n Consilium Strategic Communications\n \n \n \n +44 20 3709 5700\n \n \n Mary-Jane Elliott / David Daley / Davide Salvi\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n Notes for editors:\n \n \n \n \n \n \n \n \n \n About Allergy Therapeu...